What changed
What changedOn November 4, 2026, Taha Kass-Hout, chief science and technology officer at GE HealthCare Technologies Inc., announced his resignation. The same day, former officer James Saccaro filed a notice of a proposed sale of 78,348 shares.

What changedOn October 28, 2026, GE HealthCare reported third-quarter financial results, posting diluted earnings per share (EPS) of $1.36 and quarterly revenue of $5,513 million. Simultaneously, the company announced plans to acquire SOFIE Biosciences for $945 million in cash and leadership changes at the Patient Care Solutions division.

What changedGE HealthCare announced the appointment of Pascal Desroches, chief financial officer of AT&T, to its Board of Directors, effective January 4, 2027, and chief financial officer William K. Grogan purchased 75,096 shares and 31,877 derivative instruments on September 14, 2026.

Company history
October 2026
GE HealthCare Technologies Inc.: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-28: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 5,513,000,000 USD (5.5 billion; 5,513 million); same period a year earlier (2025-07-01 to 2025-09-30): 5,143,000,000 USD (5.1 billion; 5,143 million); change +7.2% Source
- 2026-10-28: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 15,939,000,000 USD (15.9 billion; 15,939 million); same period a year earlier (2025-01-01 to 2025-09-30): 14,927,000,000 USD (14.9 billion; 14,927 million); change +6.8% Source
- 2026-10-28: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 2,224,000,000 USD (2.2 billion; 2,224 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,990,000,000 USD (2 billion; 1,990 million); change +11.8% Source
- 2026-10-28: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 6,381,000,000 USD (6.4 billion; 6,381 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,987,000,000 USD (6 billion; 5,987 million); change +6.6% Source
- 2026-10-28: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 805,000,000 USD (805 million); same period a year earlier (2025-07-01 to 2025-09-30): 653,000,000 USD (653 million); change +23.3% Source
- 2026-10-28: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,058,000,000 USD (2.1 billion; 2,058 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,936,000,000 USD (1.9 billion; 1,936 million); change +6.3% Source
- 2026-10-28: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 1,564,000,000 USD (1.6 billion; 1,564 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,495,000,000 USD (1.5 billion; 1,495 million); change +4.6% Source
- 2026-10-28: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 320,000,000 USD (320 million); same period a year earlier (2025-07-01 to 2025-09-30): 292,000,000 USD (292 million); change +9.6% Source
- 2026-10-28: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 988,000,000 USD (988 million); same period a year earlier (2025-01-01 to 2025-09-30): 937,000,000 USD (937 million); change +5.4% Source
- 2026-10-28: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 1,365,000,000 USD (1.4 billion; 1,365 million); same period a year earlier (2025-01-01 to 2025-09-30): 937,000,000 USD (937 million); change +45.7% Source
- 2026-10-28: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 2,826,000,000 USD (2.8 billion; 2,826 million); previous balance (2025-12-31): 4,492,000,000 USD (4.5 billion; 4,492 million); change -37.1% Source
- 2026-10-28: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 11,614,000,000 USD (11.6 billion; 11,614 million); previous balance (2025-12-31): 10,379,000,000 USD (10.4 billion; 10,379 million); change +11.9% Source
September 2026
GE HealthCare Technologies Inc.: 7 recorded developments from 2 official sources in 2026-09.
- 2026-09-22: GE HealthCare announced the appointment of Pascal Desroches to its Board of Directors, effective January 4, 2027. Source
- 2026-09-22: Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors. Source
- 2026-09-22: The Company will also enter into an indemnification agreement with Mr. Desroches. Source
- 2026-09-22: There is no arrangement or understanding between Mr. Desroches and any other person pursuant to which he was selected as a director. Source
- 2026-09-22: On September 22, 2026, the Company issued a press release announcing the appointment of Pascal Desroches to its Board. Source
- 2026-09-22: A copy of the press release is furnished as Exhibit 99. Source
- 2026-09-22: The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Taha Kass-Hout will resign as Chief Science and Technology Officer, with his last day at GE HealthCare being December 31, 2026.
Said November 5, 2026 · Period named: December 31, 2026 · Source · Our article
Not yet checked against later reports.
GE HealthCare raised its full-year 2026 guidance for Organic Revenue Growth to approximately 4.0%.
Said October 28, 2026 · Period named: full-year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article
GE HealthCare raised its full-year 2026 guidance for Adjusted EPS to $4.95 - $5.05.
Said October 28, 2026 · Period named: full-year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article
GE HealthCare raised its full-year 2026 guidance for Free Cash Flow to $1.6B+.
Said October 28, 2026 · Period named: full-year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article
GE HealthCare raised its full-year 2026 guidance for Adjusted EBIT Margin to 15.5% - 15.7%.
Said October 28, 2026 · Period named: full-year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article
GE HealthCare expects its acquisition of SOFIE Biosciences to close in the first half of 2027, subject to customary closing conditions and regulatory approvals.
Said October 28, 2026 · Period named: first half of 2027 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| November 5, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| October 28, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| September 22, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| August 18, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 37,336,302 | $2,440,674,082 | -0.4% | Q3 2026 |
| State Street | 20,997,119 | $1,372,581,669 | +0.6% | Q3 2026 |
| Geode Capital Management | 12,938,406 | $842,605,888 | +0.5% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 5,823,524 | $372,763,771 | — | Q2 2026 |
| Fidelity (FMR) | 4,338,926 | $283,635,567 | +37.5% | Q3 2026 |
| Citadel Advisors | 1,744,748 | $114,054,177 | -26.3% | Q3 2026 |
| Millennium Management | 796,855 | $52,090,411 | +175.1% | Q3 2026 |
| D. E. Shaw & Co. | 418,089 | $26,761,877 | -11.1% | Q2 2026 |
| Capital Research Global Investors | 380,821 | $24,894,273 | -3.4% | Q3 2026 |
| Renaissance Technologies | 254,100 | $18,086,838 | — | Q1 2026 |
| Wellington Management | 109,311 | $7,145,660 | +1.8% | Q3 2026 |
| Bridgewater Associates | 14,808 | $967,999 | -5.0% | Q3 2026 |
| Two Sigma Investments | 12,127 | $792,742 | -6.6% | Q3 2026 |
| T. Rowe Price | 1,063,692 | $69,534 | -4.5% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.